Regeneron Pharmaceuticals REGN Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's accounts receivable?
- Regeneron Pharmaceuticals (REGN) reported accounts receivable of $5.73B in Q1 2026.
- How has Regeneron Pharmaceuticals's accounts receivable changed year-over-year?
- Regeneron Pharmaceuticals's accounts receivable increased by 3.1% year-over-year, from $5.56B to $5.73B.
- What is the long-term trend for Regeneron Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's accounts receivable has grown at a 6.9% compound annual growth rate (CAGR), from $4.11B to $5.74B.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.